Advances in myasthenia gravis.


Journal Article (Review)

Recent advances in the diagnosis and treatment of acquired myasthenia gravis (MG) are reviewed. Increased awareness about the need for more uniform methods of reporting treatment trials for MG has prompted systematic review of the literature and inspired an effort to develop better classifications and disease-specific outcome measures. New antibodies have been discovered in patients with seronegative MG, possibly defining an immunologically distinct form of the disease. A new immunosuppressant, mycophenolate mofetil, may be an additional and safe option in the treatment of MG. Other work supports the possibility of developing a vaccine against MG suitable for trial in humans.

Full Text

Duke Authors

Cited Authors

  • Ciafaloni, E; Sanders, DB

Published Date

  • January 2002

Published In

Volume / Issue

  • 2 / 1

Start / End Page

  • 89 - 95

PubMed ID

  • 11898588

Pubmed Central ID

  • 11898588

International Standard Serial Number (ISSN)

  • 1528-4042


  • eng

Conference Location

  • United States